| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121, 2018 | 3975 | 2018 |
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ... New England journal of medicine 372 (8), 724-734, 2015 | 2369 | 2015 |
| Trastuzumab emtansine for residual invasive HER2-positive breast cancer G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ... New England Journal of Medicine 380 (7), 617-628, 2019 | 2333 | 2019 |
| Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ... The lancet oncology 19 (1), 40-50, 2018 | 1781 | 2018 |
| Association analysis identifies 65 new breast cancer risk loci K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ... Nature 551 (7678), 92-94, 2017 | 1408 | 2017 |
| Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early … A Schneeweiss, S Chia, T Hickish, V Harvey, A Eniu, R Hegg, C Tausch, ... Annals of oncology 24 (9), 2278-2284, 2013 | 1318 | 2013 |
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk K Michailidou, P Hall, A Gonzalez-Neira, M Ghoussaini, J Dennis, ... Nature genetics 45 (4), 353-361, 2013 | 1284 | 2013 |
| Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay I Baccelli, A Schneeweiss, S Riethdorf, A Stenzinger, A Schillert, V Vogel, ... Nature biotechnology 31 (6), 539-544, 2013 | 1198 | 2013 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo … SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ... The lancet oncology 14 (6), 461-471, 2013 | 1149 | 2013 |
| Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The lancet oncology 21 (1), 44-59, 2020 | 1132 | 2020 |
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ... The lancet oncology 15 (7), 747-756, 2014 | 1125 | 2014 |
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic … DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ... Journal of clinical oncology 28 (20), 3239-3247, 2010 | 1089 | 2010 |
| Polygenic risk scores for prediction of breast cancer and breast cancer subtypes N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ... The American Journal of Human Genetics 104 (1), 21-34, 2019 | 976 | 2019 |
| Breast cancer risk genes—association analysis in more than 113,000 women Breast Cancer Association Consortium New England Journal of Medicine 384 (5), 428-439, 2021 | 712 | 2021 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 697 | 2020 |
| Circulating tumor cells predict survival in early average-to-high risk breast cancer patients B Rack, C Schindlbeck, J Jückstock, U Andergassen, P Hepp, T Zwingers, ... Journal of the National Cancer Institute 106 (5), dju066, 2014 | 695 | 2014 |
| Prediction of breast cancer risk based on profiling with common genetic variants N Mavaddat, PDP Pharoah, K Michailidou, J Tyrer, MN Brook, MK Bolla, ... Journal of the National Cancer Institute 107 (5), djv036, 2015 | 687 | 2015 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 673 | 2017 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 656 | 2013 |
| A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results … S Loibl, M Untch, N Burchardi, J Huober, BV Sinn, JU Blohmer, ... Annals of Oncology 30 (8), 1279-1288, 2019 | 572 | 2019 |
